Paola van der Meijden

Assistant Professor

Initially trained in Biological Health Sciences at Maastricht University, Dr Paola van der Meijden has obtained a PhD in Biochemistry on the interaction mechanisms of platelets and coagulation; focus on P2Y12receptor and factor XII.

In 2010, she acquired a unique bridging position, encapsulated within the Maastricht Thrombosis Expertise Center (TEC), aiming to link basic research on thrombosis and hemostasis with clinical research and applications. In 2014, she received the ISTH-EHA Fellowship to gain new insights into the determinants of bleeding in patients with thrombocytopenia due to hematological malignancies and chemotherapy. The focus of her current work is on the interactions between platelets and coagulation in acquired hemostatic dysfunction as a consequence of disease and treatment. She has a special interest in the negative and positive priming of platelets and the functional specialisation of platelet populations. Overall, knowledge on the factors contributing to hemostasis and thrombosis enables the development of predictive and diagnostic tests, resulting in improved disease management.

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room: 4.322
T: +31(0)43 388 16 84

  • 2022
    • De Simone, I., Baaten, C. C. F. M. J., Jandrot-Perrus, M., Gibbins, J. M., Ten Cate, H., Heemskerk, J. W. M., Jones, C. I., & van der Meijden, P. E. J. (2022). Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1. International journal of molecular sciences, 23(18), [10203].
    • Veninga, A., Handtke, S., Aurich, K., Tullemans, B., Brouns, S., Schwarz, S. L., Heubel-Moenen, F. C., Greinacher, A., Heemskerk, J. W. M., van der Meijden, P., & Thiele, T. (2022). GPVI expression is linked to platelet size, age, and reactivity. Blood advances, 6(14), 4162-4173.
    • Lundstroem, A., Sanden, P., Mitroulis, I., & van der Meijden, P. E. J. (2022). Editorial: Platelet Function in COVID-19. Frontiers in cardiovascular medicine, 9, [912472].
    • Veninga, A., Baaten, C. C. F. M. J., De Simone, I., Tullemans, B. M. E., Kuijpers, M. J. E., Heemskerk, J. W. M., & van der Meijden, P. E. J. (2022). Effects of Platelet Agonists and Priming on the Formation of Platelet Populations. Thrombosis and Haemostasis, 122(05), 726-738.
    • Brouns, S. L. N., Tullemans, B. M. E., Bulato, C., Perrella, G., Campello, E., Spiezia, L., van Geffen, J. P., Kuijpers, M. J. E., van Oerle, R., Spronk, H. M. H., van der Meijden, P. E. J., Simioni, P., & Heemskerk, J. W. M. (2022). Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow. Research and practice in thrombosis and haemostasis, 6(2), [e12678].
    • Tullemans, B. M. E., Fernandez, D. I., Veninga, A., Baaten, C. C. F. M. J., Peters, L. J. F., Aarts, M. J. B., Eble, J. A., Campello, E., Spiezia, L., Simioni, P., van der Vorst, E. P. C., van der Meijden, P. E. J., Heemskerk, J. W. M., & Kuijpers, M. J. E. (2022). Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. Thrombosis and Haemostasis, 122(01), 92-104.
    • Vignoli, A., Gamba, S., van der Meijden, P. E. J., Marchetti, M., Russo, L., Tessarolo, S., Giaccherini, C., Swieringa, F., Cate, H. T., Finazzi, G., Heemskerk, J. W. M., & Falanga, A. (2022). Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. Blood Transfusion, 20(2), 143-151.
  • 2021
    • Hulshof, A-M., Olie, R. H., Vries, M. J. A., Verhezen, P. W. M., van der Meijden, P. E. J., Ten Cate, H., & Henskens, Y. M. C. (2021). Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention. Frontiers in cardiovascular medicine, 8, [788137].
    • Tullemans, B. M. E., Veninga, A., Fernandez, D. I., Aarts, M. J. B., Eble, J. A., van der Meijden, P. E. J., Heemskerk, J. W. M., & Kuijpers, M. J. E. (2021). Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment. International Journal of Molecular Sciences, 22(20), [11199].